Details for Patent: 6,794,410

Which drugs does patent 6,794,410 protect, and when does it expire?

Patent 6,794,410 protects AUBAGIO and is included in one NDA.

Protection for AUBAGIO has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has nineteen patent family members in eighteen countries.

Summary for Patent: 6,794,410

Title:	Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis
Abstract:	The invention relates to the use of compound of Formula I in treating patients for the symptoms of multiple sclerosis. ##STR1##
Inventor(s):	Wettstein; Joseph (Lebanon, NJ)
Assignee:	Aventis Pharmaceuticals Inc. (Bridgewater, NJ)
Application Number:	10/113,078
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 6,794,410
Patent Claim Types: see list of patent claims	Use;

Drugs Protected by US Patent 6,794,410

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Sanofi Aventis Us	AUBAGIO	teriflunomide	TABLET;ORAL	202992-001	Sep 12, 2012	AB	RX	Yes	No					Y
Sanofi Aventis Us	AUBAGIO	teriflunomide	TABLET;ORAL	202992-002	Sep 12, 2012	AB	RX	Yes	Yes					Y

Foreign Priority and PCT Information for Patent: 6,794,410

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
United Kingdom	0123571	Oct 02, 2001

International Family Members for US Patent 6,794,410

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	033459
Austria	396719
Canada	2443285
Cyprus	1110446